FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL											
	OMB Number:	3235-0287										
	Estimated average burden											
- 1	hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Albors, Loffroy, W.							2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [BPMC]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Albers Jeffrey W.														r	10% (	Owner			
(Last) (First) (Middle)							Date of Earliest Transaction (Month/Day/Year)							(give title	Other below	(specify			
, ,	IEDDIN	`	EDICINES CO	` '	TION		03/04/2021							CEO and President					
				IKI OKA.	HON														
45 SIDN	EY SIR	EE	I																
(Street)						4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							vidual or Joint/Group Filing (Check Applicable					
CAMBRIDGE MA 02139												Form fi	Form filed by One Reporting Person						
———				02100										Form filed by More than One Reporting Person					
(City)		(St	ate)	(Zip)								Person	ı						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Da					2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securitie Disposed C		and 5) Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	tion(s)		(Instr. 4)			
Common	Stock				03/04	2021		M <sup>(1)</sup>		10,000	A	\$8.8	191	,434	D				
Common Stock 03/04/20						2021		S <sup>(1)</sup>		1,100	D	\$93.210	2) 190	),334	D				
Common Stock 03/04/2								S <sup>(1)</sup>		5,296	D	\$91.780	185	5,038	D				
Common Stock 03/04/20						2021		S <sup>(1)</sup>		3,000	D	\$90.990	<sup>4)</sup> 182	2,038	D				
Common Stock 03/04/2								S <sup>(1)</sup>		404	D	\$90.180	5) 181	,634	D				
Common Stock 03/04/2								S <sup>(1)</sup>		100	D	\$89.18	181	,534	D				
Common Stock 03/04/2								S <sup>(1)</sup>		100	D	\$86.61	181	,434	D				
Common Stock 03/04/2								S <sup>(6)</sup>		569	D	\$88.630	7) 180	,865	D				
Common Stock 03/04/2								S <sup>(6)</sup>		8,417	D	\$86.61	172	2,448	D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security	2. Conversi or Exerci		3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any	Date,	I. Fransacti Code (Ins		Expirati	6. Date Exercisable an Expiration Date (Month/Day/Year)		of Securities		8. Price of Derivative Security	9. Number derivative Securities	Ownersh	11. Nature of Indirect Beneficial			

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Seci Acq (A) ( Disp of (E	umber vative urities uired or oosed o) (Instr. and 5)	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$8.8	03/04/2021		M <sup>(1)</sup>			10,000	(8)	02/10/2025	Common Stock	10,000	\$0	7,170	D	

## **Explanation of Responses:**

- 1. Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$92.69 to \$93.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) and footnote (7) to this Form 4.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$91.31 to \$92.30 per share.
- 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$90.37 to \$91.30 per share.
- 5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$90.02 to \$90.27 per share.
- 6. This sale represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- 7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$88.34 to \$89.15 per share.
- 8. This option was granted on February 10, 2015 and is fully vested as of the date hereof.

/s/ Christopher Frankenfield, Attorney-in-Fact

03/05/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.